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Abstract  
Background: Breast Cancer (BC) is primarily considered a genetic disorder with a complex 
interplay of factors including age, gender, ethnicity, family history, personal history and 
lifestyle with associated hormonal and non-hormonal risk factors. The SNP rs2910164 in 
miR146a (a G to C polymorphism) was previously associated with increased risk of BC in 
cases with at least a single copy of the C allele in breast cancer, though results in other 
cancers and populations have shown significant variation. Methods:  In this study, we 
examined this SNP in an Australian sporadic breast cancer population of 160 cases and 
matched controls, with a replicate population of 403 breast cancer cases using High 
Resolution Melting. Results: Our analysis indicated that the rs2910164 polymorphism is 
associated with breast cancer risk in both a primary and replicate population (p= 0.03 and 
0.0013, respectively). In contrast to the results of familial breast cancer studies, however, we 
found that the presence of the G allele of rs2910164 is associated with increased cancer risk, 
with an OR of 1.77 (95% CI 1.40-2.23). Conclusions: The microRNA miR146a has a 
potential role in the development of breast cancer and the effects of its SNPs require further 
inquiry to determine the nature of their influence on breast tissue and cancer. 
 
Highlights: 
• Examination of a SNP in a microRNA affecting the mature miRNA sequence 
• SNP has been previously associated with familial cancer and lowered age at 
diagnosis. 
• G Allele associated with increase breast cancer risk in two independent populations. 
• Divergence from familial results may indicate that BRCA functionality may be 
involved in the action of this SNP 
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1. Introduction 
Breast cancer (BC) is the leading cause of death amongst Australian women with risk 
increasing with age and with an average age of diagnosis of 60 years [1]. BRCA1 and BRCA2 
are the two most commonly associated genes in familial BC. With familial BC cases 
comprising only 5-10% of all BC cases, sporadic BC cases have a much higher incidence rate 
[2]. Causes of sporadic BC are not yet clearly understood and it is regarded as the more 
complex form of the disease. miRNAs are a highly conserved class of small (~22 
nucleotides), endogenous, non-protein coding RNAs recently found to play a role not only in 
BC but also in various other cancers. These miRNAs bind to target mRNA regions where 
they can both inhibit transcription or initiate mRNA cleavage [3,4]. Depending on target 
interaction, miRNAs can be classified as either cancer causing (oncogenic) or tumour-
suppressing (non-oncogenic). Polymorphisms in miRNAs potentially alter these interactions 
by interfering, generating or removing miRNA-binding sites as well as affecting expression 
of miRNAs. Thus, these polymorphisms have the potential to significantly alter how the 
miRNA interacts with its target/s and its affect on cellular biology. Consequently, the 
identification of these SNPs and their association with disease susceptibility could be used for 
improved diagnostic and therapeutic strategies.  
miR146a is an miRNA located on human chromosome 5 at locus 5q34 and has been linked 
with BRCA1/BRCA2 activity, as these are among its potential targets. The SNP rs2910164 is 
located in the middle of the stem hairpin in the miRNA and leads to a G:U pair mismatch 
(instead of C:U) in the structure of miR146a. In a study by Shen et al [5], this polymorphism 
was linked with age of diagnosis in breast and ovarian cancer patients and was the first 
research to show association of miR146a with breast cancer. The study reported that the 
presence of at least one C allele lowered the age of diagnosis in BC patients with the level of 
expression of mature miR146a 60% higher in C allele carriers (n= 124 white Caucasian 
women, 42 diagnosed with familial BC, 82 diagnosed with ovarian cancer). In addition the 
authors identified an association of miR146a with BRCA1/BRCA2 by confirming that 
miR146a could directly bind to the 3’UTR of both genes and therefore play a role in 
regulating their expression. Interestingly, a similar study conducted by Hu et al. [6] in 2009 
on Han Chinese familial BC cases (n=1009), produced contradictory results. In the Hu et al 
study, although a much larger cohort was examined, no association of the miR146a SNP with 
age of BC diagnosis was demonstrated; suggesting the effect of genotype or alleles for the 
SNP rs2910164 may be population specific or modulated by environmental factors. In 2010, 
Pastrello et al conducted a similar study on Italian patients diagnosed with familial BC and 
negative for BRCA1/BRCA2 mutations (n=101) to ascertain if rs2910164 had any association 
with age of diagnosis [7]. Their results confirmed those by Shen et al and contradict those 
found by Hu et al [5, 6]. In addition, a study by Alshatwi et al in Saudi-Arabian breast cancer 
patients indicated that while miR146a expression was significantly altered in breast cancer 
patients compared to controls, rs2910164 did not appear to be associated with breast cancer 
risk, though their population was only 100 individuals and the ages of some of their patients 
indicated a potential familial aspect in these cases [8]. Due to the variations in these studies 
and the lack of research in a purely sporadic population of breast cancer patients in 
Caucasians, we examined this SNP in a case-control Australian Caucasian sporadic breast 
cancer population.  
 
2. Materials and methods 
2.1. Study Cohort 
The study population consisted of 160 Caucasian Australian females, who were recruited on a 
voluntary basis with the criteria of being diagnosed with sporadic breast cancer, showing no 
family history of the disease. These women were matched for age (±5 years), Caucasian 
ethnicity and sex to a control cohort of healthy individuals likewise showing no family 
history of breast or related cancers. Case samples were recruited from the Gold Coast 
Hospital, Southport, Australia, inviting all women with breast cancer attending to participate. 
Control samples were recruited by the Genomics Research Centre Clinic, Southport, 
Australia by invitation for healthy women from the community to volunteer for the research. 
All participants in these populations were recruited from the south-east Queensland area at 
the same time. 
The secondary replication population consisted of 403 sporadic breast cancer patient samples 
obtained from the Griffith University-Cancer Council Queensland Breast Cancer Biobank. 
These individuals were all those currently available, recruited on a prevalence basis, but with 
confirmed diagnosis on the Queensland Cancer Registry. The secondary population consisted 
of an additional 89 healthy controls, representing the currently available healthy women 
volunteers, recruited and matched on a first-available-match basis to one of the cases as for 
the primary population (age (±5 years), ethnicity and sex). Controls for this population were 
primarily from the south-east Queensland region, while cases were recruited Queensland 
wide. Both cases and controls for these populations were recruited at the same time. 
 
The project was carried out with the approval of the Griffith University Human Research 
Ethics Committee, approval numbers: MSC/07/08/HREC and PSY/01/11/HREC and the 
Queensland University of Technology Human Research Ethics Committee, approval number: 
1400000104. All participants supplied informed written consent. 
 
2.2. Genotyping   
The candidate SNP in this study was identified using dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP). Primers were designed using Primer3 
(http://frodo.wi.mit.edu/) and checked for specificity through BLAST 
(http://blast.ncbi.nlm.nih.gov). The SNPs were genotyped using high resolution melt (HRM) 
analysis on a RotorGene-Q (Qiagen, Australia). The primer sequences used were: forward 5’-
TTACAGGGCTGGGACAG-3', reverse-5' -CCTCAAGCCCACGATGA-3'. PCR 
amplification and HRM analyses were carried out in a 12µL reaction containing: 2µL of 
20ng/µL genomic DNA, 1µL of 10µM each forward and reverse primers, 2.3µL of 25mM 
MgCl2, 0.8µL of 5µM dNTPs, 2.4µL of 5X GoTaq Buffer, 0.1µL of 5Units/µL GoTaq and 
1.75µL dH2O. PCR conditions were: 95oC for 1 minute, followed by 40 cycles of 95oC for 15 
seconds, 62oC for 15 seconds and 75oC for 30 seconds, followed by 7 minutes at 72oC. 
Melting analysis was carried out between 78oC and 86oC with data collected every 0.1oC. 
Two negative controls and two positive controls (Homozygous G and Heterozygous CG) 
were included in each run to ensure a maintained high quality of genotyping. Each sample 
was performed in duplicate, and in batches of sequential samples. Case and control samples 
were genotyped simultaneously for some reactions and separately for others, depending on 
overlap between sequential batches on storage plates. Sanger Sequencing (DNS) was used on 
a random selection of four of each genotype in each population for validation of genotypes 
identified by HRM.  
 
Following HRM, the number of samples that were able to be accurately genotyped was 143 
cases and 157 controls for the primary population and the full 403 cases and 89 controls for 
the secondary population. Samples which were unable to provide an unambiguous genotype 
result or would not amplify in PCR for direct sequencing were discarded. 
 
2.3. Statistical Analysis  
Analysis was undertaken using chi-square analysis in the SPSS statistics package. Analysis 
for genotype and allele effects was undertaken using the Chi-square test of independence and 
Odds Ratios and 95% confidence intervals were calculated from the combined results of both 
populations. All populations also underwent testing for Hardy Weinberg equilibrium. The α 
was set at 0.05. We assessed possible heterogeneous association across the populations using 
the Breslow-Day test as implemented in PLINK (v1.04) (Purcell, 2007) In addition, 
comparison of population characteristics was performed using an independent samples t-test 
(using Levene’s test for equality of variances) for continuous variables and an additional Chi-
square test for categorical variables.  
 
3. Results  
The case and control populations had average ages of 58.00±12.00 and 57.50±11.60 years, 
respectively. These ages are not significantly different from one another. Available data on 
the population, including risk parameters of body mass index, age at menarche, number of 
pregnancies, number of children breastfed and use of hormone replacement therapy can be 
found in Table 1. Biobank samples and controls had average ages of 61.09±25.09 and 
60.20±28.20 years, respectively. These ages are not significantly different from one another. 
Risk parameters were not available for this population. The difference in average ages 
between the Genomics Research Centre and Queensland Cancer Registry populations is 
significant at p<0.0001, however.  
 
Following detection by HRM and sequencing validation, we obtained and compared the 
observed genotypic and allelic frequencies for rs2910164 between the case and control 
populations. There were some shifts in genotype frequencies between the case and control 
populations, with the C allele approximately 10% rarer in the case population, reflected in 
decreases in the CC and GC genotypes in cases compared to controls, as seen in Table 2. 
Hardy-Weinberg analysis indicated that both populations were in Hardy-Weinberg 
equilibrium. Chi square analysis indicated that the genotype differences were not significant, 
but that allelic frequencies between the populations were significantly altered (p= 0.11 and 
0.03 respectively).  
Because the primary breast cancer population showed a significant association between 
rs2910164 alleles and breast cancer susceptibility, we undertook genotyping in our secondary 
Biobank population.  The results of this genotyping showed a similar trend, with the C allele 
being approximately 10% rarer in the case population compared to the controls, with both CC 
and GC genotypes rarer in the case population compared to controls (Table 2). As for the 
initial population, both case and control populations for the secondary analysis were in 
Hardy-Weinberg equilibrium. Chi square analysis on the secondary association population 
indicated that the differences between cases and controls were significant for both genotype 
and allelic frequencies, at p= 0.00088 and 0.0013, respectively.  
No significant differences were observed between the Primary and Biobank collections 
(Breslow-Day test, Phet > 0.05). 
Since both populations showed significant association with breast cancer susceptibility, we 
undertook odds ratio calculations to determine the magnitude of the effect. All three models 
tested (G vs. C for additive, GG vs. GC+CC for recessive and GG+GC vs. CC for dominant 
inheritance models) showed increases in breast cancer risk associated with a higher dose of 
the G allele, with the G vs. C model showing the most precise odds estimate, with an OR of 
1.77 (95% CI 1.40 - 2.24). A summary of combined statistical analysis for both populations 
can be found in Table 2 and the complete Odds Ratios can be found in Table 3. 
 
.  
 
 
4. Discussion 
Our results indicate that the presence of the G allele for rs2910164 increases the risk for 
sporadic breast cancer in a Caucasian population, confirmed through analysis in two 
independently collected populations. These results show some deviation from the expected 
frequency of the C allele in the general population compared to reported frequencies for the 
rs2910164 SNP in Caucasian populations. The reported allelic frequency as per the 1000 
Genomes Project in Europeans is G-78.2% and C-21.8%, while HapMap gives frequencies of 
G-76.5% and C-23.5%. Data from other populations in both the 1000 Genomes Project and 
HapMap, however, show that rs2910164 varies significantly in different ethnic groups, and in 
Asians, the most common allele is C, with frequencies of C-60% and G-40%. More 
importantly for this research, a subset breakdown within the European population shows that 
Italians have an increased frequency of the C allele compared to other European groups, at C-
27% and G-73%. It thus seems possible that our elevated C allele count is the result of a 
contribution from Italian and related Caucasian subgroups, especially given that sequencing 
of HRM analysed samples showed confirmation of the genotype calls in both cancer and 
control populations. This is an important consideration for research into this polymorphism, 
because different populations with different ethnic backgrounds may have quite different 
allele distributions, which will result in altered interaction with environmental effects. It is 
perhaps for this reason that the published data on this SNP to date has come from familial 
studies. 
In addition, the results of our population comparison and logistic regression analysis 
indicated that none of the potential risk factors for breast cancer, such as body mass index, 
age at menarche, number of pregnancies, number of children breastfed, menopausal or HRT 
use status significantly impact upon our analysis of the effect of rs2910164 in terms of 
primary risk. While these factors may interact with rs2910164 to some degree, the relative 
similarity of our case and control populations has reduced any confounding effects to a 
minimum. 
Our results show some variation from the implications of previous research on rs2910164 in 
breast cancer, though those studies have also shown conflicting results. In 2008, Shen et al 
identified an increased risk of breast cancer amongst patients who had a single copy of the C 
allele and that the binding capacity of miR146a to BRCA1 was significantly higher in vitro 
when cells were transfected with C allele mimics as compared to the G allele [5]. These 
results led them to draw the conclusion that the CC or CG variant of the rs291016 
polymorphism increases susceptibility to familial BC. A similar study conducted by Hu et al 
in 2009 found contrasting results [6]. The Hu et al study involved 1009 familial breast cancer 
patients and 1093 healthy controls from a Han Chinese population. In this study, no 
association of miR146a with increased risk of familial breast cancer was observed. More 
recently, a study conducted by Catucci et al in 2010 on 1894 familial breast cancer patients 
and 2760 healthy controls from German and Italian populations also demonstrated no 
association with increased risk of familial breast cancer and miR146a [9]. The discrepancy 
between the results obtained from previous studies, including the current study may be due to 
the varied ethnic backgrounds investigated, however, the observed differences are more 
likely a result of fundamental differences in the type of breast cancer addressed in the 
population cohorts examined.  
This difference is that each of the previous breast cancer association studies have been carried 
out in populations of individuals with familial cancer, most of whom show symptoms of 
BRCA pathway malfunction, but lack BRCA1 or BRCA2 mutations. The suggested 
association of miR146a with increased risk of breast cancer by Shen et al in 2008 was a result 
of a study conducted on patients with BRCA1/BRCA2 mutations, indicating familial breast 
cancer where these genes are known to play an essential role [5]. In addition, the study by 
Pastrello et al where BRCA-negative patients were examined supports the data observed by 
Shen et al for the effects of the C allele on age of onset [5, 7]. Similar to the study by Shen et 
al and Alshatwi et al, the Pastrello et al study cohort was a much smaller population when 
compared to the studies conducted by Hu et al and Catucci et al [5-9]. Finally, a study on 
1166 BRCA1 mutation carriers and 560 BRCA2 mutation carriers from France and America 
(no ethnicity specified) by Garcia et al on failed to find an association between rs2910164 
and cancer risk in these patients. miR146a has thus been variably associated with 
BRCA1/BRCA2 familial BC risk, age of onset and age of diagnosis in these studies. Meta-
analyses on the BC studies to date indicate that both ethnicity and gender is a factor in the 
effect of rs2910164 on cancer susceptibility [10, 11]. This would make sense in the context of 
recent results from Omrani et al. who tested the rs2910164 SNP in an Iranian breast cancer 
population and failed to find any association with the alleles and breast cancer [12]. 
The conflicting results of previous studies may arise through differential effects of the SNP in 
the background of a familial impairment of BRCA1 and 2 associated pathways compared to 
non-impairment of these pathways in sporadic breast cancer patients. If BRCA associated 
pathways are poorly functional in familial breast cancer patients, then the effect of the 
increased BRCA1/BRCA2 binding for the C allele of rs2910164 may result in greater loss of 
cell growth regulation. By comparison, in sporadic breast cancer the increased binding of the 
C allele may be compensated for by upregulation of the precise BRCA related mechanisms 
that are impaired in familial patients. This would lead to a situation where the control 
populations used to determine association for the familial populations are subject to allelic 
pressure in the same direction, partially masking the effect of the SNP on risk in these 
patients.  
There is also support for differential biological effects for the SNP from data gathered in 
other cancer types. In head and neck cancers, colorectal cancer, acute lymphoblastic 
leukaemia and H. pylori infection related dysplasia, the C allele of rs2910164 has been 
associated with increased risk of development [13-18]. By contrast, the G allele has been 
associated with increased risk of hepatocellular carcinoma and prostate cancer, while 
melanomas showed a more complex relationship where heterozygotes had increased risk of 
cancer development, but cells carrying the G allele had increased invasive and proliferative 
characteristics [19-22]. These differences add weight to the implications from the breast 
cancer studies suggesting that the effect of the polymorphism is modulated by genetic and 
environmental factors, probably due to the relative expression of its target mRNAs and 
factors affecting its own expression. In addition, there may be significant effects on the effect 
of miR146a through the presence or absence of BRCA1 or BRCA2 mutations, epistatic effects 
from other SNPs, or specific environmental triggers common to closely related individuals 
compared to more sporadic population cohorts. These in turn may influence the overall 
impact of the rs2910164 SNP on breast cancer susceptibility, despite its observed functional 
effects.  
Our study has several limitations. One of those which may be fundamental to studies on 
rs2910164 is ethnic variation of the SNP, where allele frequency differs strongly and this in 
combination with environmental effects may obscure the true relationship of the 
polymorphism and breast cancer risk. Our controls were collected from a similar background 
population, which should control for this to some degree, and the similarity of our 
participants for risk parameters would support this, but the effect is likely still there. In 
addition, our study does not have a complete picture of all the risk factors for all participants, 
and there is a lack of specific clinical data concerning the participants’ diagnoses that may be 
of relevance to the risk of breast cancer in the context of rs2910164. This includes both 
biological factors such as exposure to estrogen, as well as behavioral and lifestyle factors 
such as smoking, diet and exercise. This limits the ability to generalize the results of the 
study. Further studies examining behavioral and clinicopathological features in more depth 
for sporadic breast cancer patients may be of use in determining the true effect of rs2910164 
on breast cancer risk. 
Leading on from this, our relatively low sample size may also be affecting overall accuracy 
of the study, especially in the lack of controls available for the secondary population. 
Similarly, our two study cohorts show a difference in average age. We attribute this 
difference to the different collection methods for the cohorts, with the advertisement followed 
by consent recruitment by the Genomics Research Centre favouring a younger, more active 
population compared to the Biobank population, which was recruited through the Queensland 
Cancer Registry and as a result took in all cancer patients diagnosed in the recruitment 
period. While the effect of age on cancer development in our study should be controlled for 
through the use of the age matched controls, there is some potential for differences in the 
ages between the population to make detection of subtle effects more difficult. Additionally, 
the difference between state-wide cancer participant recruitment for the Biobank and the 
more narrow regional recruitment for their controls may introduce some bias regarding risk 
factors that are faced more in remote and rural areas compared to metropolitan and regional 
areas. This is a bias that our primary population does not share, however, and so should not 
be a consistent bias on our overall result.  As a result of these issues, research using sporadic 
breast cancer populations in larger, closely controlled cohorts of Caucasians and other 
ethnicities should be undertaken to confirm the role of rs2910164 in cancer risk in the general 
population. 
 
5. Conclusions 
Our analysis indicates that the rs2910164 SNP in miR146a has a significant effect on breast 
cancer susceptibility. Given the interaction with BRCA pathways, the potential role of other 
polymorphisms (inferred from the role of ethnicity) and the variable results of research on 
rs2910164 in breast cancer, further analyses on this polymorphism should take into account 
the potential for familial versus sporadic breast cancer effects, and should carefully choose 
controls to establish the effects of the SNP more precisely in the target populations.  
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Table and figure legends 
 
Table 1. Population Characteristics. 
 
Population Age Age at 
Menarche 
BMI Number of 
Pregnancies 
Number of 
Children 
Breastfed 
Menopausal 
Status 
Hormone Replacement 
Therapy 
Pre Post Never Current or 
Ex 
GRC Cases 58.00  
±12 
12.94  
± 10 
26.50  
± 54 
2.78  
± 9 
1.71  
± 7 
29 116 88 64 
n= 160 n=149 n=143 n=156 n=156 (20%) (80%) (58%) (42%) 
GRC 
Controls 
57.50 
±11.6 
12.97 
 ± 5 
24.80  
± 25 
2.68  
± 10 
1.77  
± 8 
8 30 25 18 
n= 160 n=43 n=44 n=44 n=44 (21%) (79%) (58%) (42%) 
Comparison  
p-value 
0.93 0.92 0.09 0.73 0.82 0.89 0.98 
 
 
 
 
  
Table 2. Primary population genotype and allele frequencies and analysis results. 
 
Population Analysis 
Cases Controls 
χ2 Sig. GG /G  GC CC /C  GG /G  GC CC /C  
Primary 
Population 
Genotype 
80 
(55.9%) 
49 
(43.3%) 
14 
(9.8%) 
70 
(44.6%) 
63 
(40.1%) 
24 
(15.3%) 
5.60 0.061 
Allele 
209 
(73.1%) 
- 
77 
(26.9%) 
203 
(64.6%) 
- 
111 
(35.4%) 
4.95 0.03 
Biobank 
Population 
Genotype 
245 
(60.8%) 
144 
(35.7%) 
14 
(3.5%) 
42 
(4.2%) 
30 
(40.4%) 
11 
(12.4%) 
14.01 0.0009 
Allele 
624 
(78.6%) 
- 
172 
(21.4%) 
120 
(67.4%) 
- 
58 
(32.6%) 
10.29 0.0013 
Combined 
Population 
Genotype 
325 
(59.5) 
193 
(35.3%) 
28 
(5.2%) 
112 
(45.6%) 
99 
(40.2%) 
35 
(14.2%) 
24.78 0.000006 
Allele 
843 
(77.2%) 
- 
249 
(22.8%) 
323 
(65.7%) 
- 
169 
(34.3%) 
23.28 0.000001 
  
Table 3. Odds Ratios for combined population analysis results. 
 
Odds Ratios OR 
(95% CI) 
Sig. 
G vs. C model 1.77 
(1.40 - 2.23) 
<0.0001 
GG vs. GC and CC 
model 
1.84 
(1.36 – 2.50) 
0.0003 
GG and GC vs. CC 
model 
3.06 
(1.82 - 5.17) 
<0.0001 
 
  
